Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable. The ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...

There are hundreds of publicly traded companies on various equity markets worldwide. Investors choose to put their ...

Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis: London Monday, March 10, 2025, 10:00 Hrs [IST] Vertex Pharmaceuticals, a ...

However, Vertex remains an attractive stock. Since that setback, the biotech has earned approval for Alyftrek, a next-generation medicine in its core area of expertise, cystic fibrosis (CF).

The company still has plenty of room to grow in the CF market, especially with its recently approved drug Alyftrek. Not only is Alyftrek more effective than Vertex's top-selling Trikafta ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Alyftrek (triple combination medicine ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...